Testing effectiveness (Phase 2)Study completedNCT00841646
What this trial is testing
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects
Who this might be right for
Prepandemic Influenza Vaccine
Novartis Vaccines 343